Lonza's chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. That marks a climb down from remarks at an investor event a month ago, when Albert Baehny said that Lonza would participate in the obesity therapy market thanks to its growing fill and finish capacity. The new obesity drugs, based on a class of peptides known as glucagon-like peptide-1 (GLP-1) receptor agonists, would not feature in Lonza's growth plans, despite the Swiss company producing a secondary ingredient for one such drug, Baehny said in an interview.
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
(Reuters) -European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.